Barclays PLC Buys 33,185 Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH)

Barclays PLC increased its position in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) by 390.5% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 41,684 shares of the company’s stock after purchasing an additional 33,185 shares during the quarter. Barclays PLC’s holdings in Dianthus Therapeutics were worth $1,141,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also bought and sold shares of DNTH. Quest Partners LLC grew its position in shares of Dianthus Therapeutics by 112,400.0% during the 3rd quarter. Quest Partners LLC now owns 1,125 shares of the company’s stock worth $31,000 after buying an additional 1,124 shares in the last quarter. The Manufacturers Life Insurance Company bought a new stake in shares of Dianthus Therapeutics in the 2nd quarter valued at about $236,000. SG Americas Securities LLC lifted its position in shares of Dianthus Therapeutics by 104.0% in the 3rd quarter. SG Americas Securities LLC now owns 8,839 shares of the company’s stock worth $242,000 after purchasing an additional 4,506 shares during the period. Fred Alger Management LLC boosted its stake in shares of Dianthus Therapeutics by 52.5% during the third quarter. Fred Alger Management LLC now owns 9,633 shares of the company’s stock valued at $264,000 after purchasing an additional 3,316 shares in the last quarter. Finally, WINTON GROUP Ltd purchased a new position in Dianthus Therapeutics during the second quarter valued at approximately $265,000. 47.53% of the stock is owned by institutional investors.

Dianthus Therapeutics Stock Down 1.1 %

Shares of DNTH opened at $22.74 on Monday. The stock’s 50-day moving average price is $25.23 and its 200-day moving average price is $26.68. The company has a market capitalization of $673.04 million, a price-to-earnings ratio of -9.10 and a beta of 1.74. Dianthus Therapeutics, Inc. has a 52 week low of $10.02 and a 52 week high of $33.77.

Dianthus Therapeutics (NASDAQ:DNTH) last issued its quarterly earnings data on Thursday, November 7th. The company reported ($0.74) EPS for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.15). Dianthus Therapeutics had a negative return on equity of 21.68% and a negative net margin of 1,250.32%. The firm had revenue of $2.17 million for the quarter, compared to analyst estimates of $1.07 million. As a group, equities analysts anticipate that Dianthus Therapeutics, Inc. will post -2.61 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts have issued reports on DNTH shares. HC Wainwright reaffirmed a “buy” rating and set a $40.00 target price on shares of Dianthus Therapeutics in a research report on Monday, November 11th. Oppenheimer increased their price target on shares of Dianthus Therapeutics from $48.00 to $52.00 and gave the company an “outperform” rating in a research report on Monday, November 11th. Raymond James raised shares of Dianthus Therapeutics to a “moderate buy” rating in a research report on Thursday, December 12th. Finally, TD Cowen assumed coverage on shares of Dianthus Therapeutics in a research note on Friday, December 20th. They issued a “buy” rating for the company. Eight equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $46.43.

Dianthus Therapeutics Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.